Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers

International Journal of Neuropsychopharmacology

Volumn 18, Issue 6, 2015, Pages 1-9

  Tudge, Luke ^a   Williams, Clare ^b   Cowen, Philip J ^b   McCabe, Ciara ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cannabinoid; fMRI; Obesity; Reward; THCv

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; PLACEBO; TETRAHYDROCANNABIVARIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CNR1 PROTEIN, HUMAN; DRONABINOL; TETRAHYDROCANNABIVARIN 9;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BECK DEPRESSION INVENTORY; BODY MASS; BOLD SIGNAL; BRAIN REGION; CACAO; CAUDATE NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EATING ATTITUDES QUESTIONNAIRE; FAWCETTT CLARKE PLEASURE SCALE; FEMALE; FOOD AVERSION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; NERVE POTENTIAL; NORMAL HUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; REWARD; SINGLE DRUG DOSE; SNAITH HAMILTON PLEASURE SCALE; STRAWBERRY; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TEMPORAL EXPERIENCE OF PLEASURE SCALE; AFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; AVOIDANCE BEHAVIOR; BRAIN; BRAIN MAPPING; CROSSOVER PROCEDURE; DRUG EFFECTS; FEEDING BEHAVIOR; FRAGARIA; FRUIT; FUNGUS; MALE; METABOLISM; MICROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSTIMULATION; PROCEDURES; TASTE; VISION; YOUNG ADULT;

ADULT; AFFECT; ANTI-OBESITY AGENTS; AVOIDANCE LEARNING; BRAIN; BRAIN MAPPING; CACAO; CANNABINOID RECEPTOR ANTAGONISTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; FEEDING BEHAVIOR; FEMALE; FRAGARIA; FRUIT; FUNGI; HEALTHY VOLUNTEERS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PHOTIC STIMULATION; RECEPTOR, CANNABINOID, CB1; REWARD; TASTE; TASTE PERCEPTION; VISUAL PERCEPTION; YOUNG ADULT;

EID: 84939133069     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu094     Document Type: Article

References (63)

1. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL (1985) Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 38:419-422.
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
3. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makri-yannis A (2008) Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 93:666-670.
4. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Effcacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713.
5. Emadi L, Jonaidi H, Hosseini Amir Abad E (2011) The role of central CB2 cannabinoid receptors on food intake in neonatal chicks. J Comp Physiol A Neuroethol Sens Neural Behav Phys-iol 197:1143-1147.
6. Faurion A, Cerf B, Le Bihan D, Pillias AM (1998) fMRI study of taste cortical areas in humans. Ann N Y Acad Sci 855:535-545.
7. Fawcett J, Clark DC, Scheftner WA, Gibbons RD (1983) Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry 40:79-84.
8. Filbey FM, Myers US, Dewitt S (2012) Reward circuit function in high BMI individuals with compulsive overeating: similarities with addiction. NeuroImage 63:1800-1806.
9. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV Axis I disorders: clinical version. Washington DC: American Psychiatric Press.
10. Friemel CM, Zimmer A, Schneider M (2014) The CB1 receptor as an important mediator of hedonic reward processing. Neu-ropsychopharmacology 39:2387-2396.
11. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994) Assessing the signifcance of focal activations using their spatial extent. Hum Brain Mapp 1:214-220.
12. Friston KJ, Glaser DE, Henson RN, Kiebel S, Phillips C, Ashburner J (2002) Classical and Bayesian inference in neuroimaging: applications. Neuroimage 16:484-512.
13. Gard DE, Kring AM, Gard MG, Horan WP, Green MF (2007) Anhe-donia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 93:253-260.
14. Garner DM, Olmsted MP, Bohr Y, Garfnkel PE (1982) The eating attitudes test: psychometric features and clinical correlates. Psychol Med 12:871-878.
15. Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabi-noid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261-267.
16. Harmer CJ, Cowen PJ (2013) 'It's the way that you look at it'-a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 368:20120407.
17. Harpaz Y, Levkovitz Y, Lavidor M (2009) Lexical ambiguity resolution in Wernicke's area and its right homologue. Cortex 45:1097-1103.
18. Haslam DW, James WP (2005) Obesity. Lancet 366:1197-1209.
19. Herkenham M, Lynn AB, de Costa BR, Richfeld EK (1991a) Neu-ronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274.
20. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991b) Characterization and localization of cannabi-noid receptors in rat brain: a quantitative in vitro autoradio-graphic study. J Neurosci 11:563-583.
21. Horder J, Harmer CJ, Cowen PJ, McCabe C (2010) Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 13:1103-1113.
22. Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Sub-ramanian KV, Shukla VG, Makriyannis A, Bergman, J (2013) Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther 344:561-567.
23. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML (2005) The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 58:843-853.
24. Levy DJ, Glimcher PW (2012) The root of all value: a neural common currency for choice. Curr Opin Neurobiol 22:1027-1038.
25. Liu X, Hairston J, Schrier M, Fan J (2011) Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 35:1219-1236.
26. Maccioni P, Pes D, Carai MA, Gessa GL, Colombo G (2008) Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-favoured beverage in rats. Behav Pharmacol 19:197-209.
27. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 19:1233-1239.
28. Mathes CM, Ferrara M, Rowland NE (2008) Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Am J Physiol Regul Integr Comp Physiol 295:R67-75.
29. Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I (2008) Identifcation of the sites of 2-arachi-donoylglycerol synthesis and action imply retrograde endo-cannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacol 54:95-107.
30. McCabe C, Cowen PJ, Harmer CJ (2009) Neural representation of reward in recovered depressed patients. Psychopharmacol (Berl) 205:667-677.
31. McCabe C, Mishor Z, Cowen PJ, Harmer CJ (2010) Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67:439-445.
32. McCabe C, Huber A, Harmer CJ, Cowen PJ (2011) The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. Psy-chopharmacol (Berl) 217:271-278.
33. McCabe C, Woffndale C, Harmer CJ, Cowen PJ (2012) Neural processing of reward and punishment in young people at increased familial risk of depression. Biol Psychiatry 72:588-594.
34. McPartland JM, Guy GW, Di Marzo V (2014) Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabi-noid system. PloS one 9:e89566.
35. Mechoulam R, Hanus LO, Pertwee R, Howlett AC (2014) Early phy-tocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 15:757-764.
36. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004) Endocannabinoids mediate presynaptic inhibition of gluta-matergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62.
37. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, Adan RA (2013) Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 18:1294-1301.
38. Mirenowicz J, Schultz W (1996) Preferential activation of mid-brain dopamine neurons by appetitive rather than aversive stimuli. Nature 379:449-451.
39. Murray E, Brouwer S, McCutcheon R, Harmer CJ, Cowen PJ, McCabe C (2014) Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacol (Berl) 231:4323-4335.
40. Nitschke JB, Sarinopoulos I, Mackiewicz KL, Schaefer HS, Davidson RJ (2006) Functional neuroanatomy of aversion and its anticipation. Neuroimage 29:106-116.
41. O'Doherty J, Kringelbach ML, Rolls ET, Hornak J, Andrews C (2001) Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 4:95-102.
42. Oldfeld RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97-113.
43. Paton JJ, Belova MA, Morrison SE, Salzman CD (2006) The primate amygdala represents the positive and negative value of visual stimuli during learning. Nature 439:865-870.
44. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
45. Riegel and Lupica (2004) Independent presynaptic and postsyn-aptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24:11070-11078.
46. Rolls ET, McCabe C (2007) Enhanced affective brain representations of chocolate in cravers vs. non-cravers. Eur J Neurosci 26:1067-1076.
47. Saker P, Farrell MJ, Adib FR, Egan GF, McKinley MJ, Denton DA (2014) Regional brain responses associated with drinking water during thirst and after its satiation. PNAS 111:5379-5384.
48. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Effcacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672.
49. Schienle A, Schafer A, Hermann A, Vaitl D (2009) Binge-eating disorder: reward sensitivity and brain activation to images of food. Biol Psychiatry 65:654-661.
50. Sim-Selley LJ, Vogt LJ, Vogt BA, Childers SR (2002) Cellular localization of cannabinoid receptors and activated G-proteins in rat anterior cingulate cortex. Life Sci 71:2217-2226.
51. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trig-well P (1995) A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167:99-103.
52. Solinas M, Goldberg SR, Piomelli D (2008) The endocannabinoid system in brain reward processes. Br J Pharmacol 154:369-383.
53. Stice E, Spoor S, Bohon C, Small DM (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322:449-452.
54. Stice E, Yokum S, Blum K, Bohon C (2010) Weight gain is associated with reduced striatal response to palatable food. J Neu-rosci 30:13105-13109.
55. Tallett AJ, Blundell JE, Rodgers RJ (2008) Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 94:422-431.
56. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005) Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917-926.
57. van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuur-man L, van Gerven J, Kahn RS, Ramsey NF (2012) Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacol (Berl) 219:981-990.
58. von Zerssen D, Strian F, Schwarz D (1974) Evaluation of depressive states, especially in longitudinal studies. Mod Probl Phar-macopsychiatry 7:189-202.
59. Wang GJ, Tomasi D, Volkow ND, Wang R, Telang F, Caparelli EC, Dunayevich E (2014) Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int J Obes 38:682-688.
60. Wang H, Lupica CR (2014) Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes. Prog Neuropsychophar-macol Biol Psychiatry 52:24-27.
61. Wilson JL, Jenkinson M, de Araujo I, Kringelbach ML, Rolls ET, Jez-zard P (2002) Fast, fully automated global and local magnetic field optimization for fMRI of the human brain. Neuroimage 17:967-976.
62. Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal ML, Martin-Santos R, Ffytche D, Zuardi AW, Atakan, Z, McGuire, PK (2011) Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacol 36:1340-1348.
63. Zald DH, Hagen MC, Pardo JV (2002) Neural correlates of tasting concentrated quinine and sugar solutions. J Neurophysiol 87:1068-1075.